-
Rituxan®
Rituxan® (rituximab) is a biologic monoclonal antibody therapy used to treat a range of autoimmune, inflammatory, and hematologic conditions. By targeting specific immune cells involved in disease activity, Rituxan® helps reduce inflammation, control symptoms, and slow disease progression.
At Singlepoint Healthcare, Rituxan® infusions are delivered in a safe, comfortable, and closely monitored setting, ensuring patients receive high-quality, personalized care throughout their treatment.
How Rituxan Works
Rituxan® works by targeting CD20-positive B cells, a type of immune cell that plays a role in autoimmune inflammation and abnormal immune responses. By reducing the number of these B cells, Rituxan® helps calm immune system activity that contributes to tissue damage and chronic symptoms.
This targeted mechanism allows Rituxan® to address the underlying drivers of disease rather than simply masking symptoms. Many patients experience fewer flare-ups, improved symptom control, and better long-term disease stability with ongoing therapy.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Non-Hodgkin’s Lymphoma, Microscopic Polyangiitis (MPA), Pemphigus Vulgaris (PV) |
| Manufacturer | Genentech |
| Administered by | Infusion |
| Frequency | ~4-6 months |
| Length of Infusion | ~2–4 hours |
| FDA Approval(s) | Non-Hodgkin's Lymphoma: Approved November 26, 1997 Microscopic Polyangiitis (MPA): Approved April 20, 2011 Pemphigus Vulgaris (PV): Approved June 7, 2018 |